Trio of Cancer Drugs Face Scrutiny of FDA Panel
Agency staff appear lukewarm on Lynparza data, supportive of Keytruda, and skeptical of tazemetostat
Related Articles
NIH Centers Slashed, Consolidated in Leaked HHS Budget Document
It’s the first clear picture of how the Trump administration would like to reshape HHS
2025 Annual Meeting – Las Vegas
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence…
Inflammatory Markers at Birth and Risk of Early-Onset Inflammatory Bowel Disease
The development of inflammatory bowel disease (IBD) may be preceded by a long preclinical phase characterized by several disease-associated immunologic changes, as observed for other…
Amid Measles Outbreaks, Poison Centers See Uptick in Vit A Exposures in Kids
RFK Jr. has touted the vitamin for the highly contagious virus
2025 Annual Meeting – Las Vegas
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence…
Join and Save – AUA Annual Meeting
Become an AUA member and SAVE up to $886 on Annual Meeting registration!
Medical Journals Get Letters From DOJ
At least three journals received letters from a U.S. Attorney asking about ‘competing viewpoints’
Medical Journals Get Letters From DOJ
At least three journals received letters from a U.S. Attorney asking about ‘competing viewpoints’
